Seemingly hardly off our pages in recent weeks, Biosensors International Group, Ltd., cardio device company has entered into a licensing agreement with Eurocor GmbH, a group company of Opto Circuits (India) Ltd. The agreement will see Biosensors market and sell, under its own brand, drug eluting balloons manufactured by Eurocor for use in coronary and peripheral artery disease.
Background
Under the terms of the deal, three Biosensors-branded DEBs will be marketed by the company: These are the BioStream™ coronary artery device, BioPath™ 014 below the knee balloon and and BioPath™ 035 for above the knee use.
All three DEBs feature Eurocor’s proprietary coating technology delivering paclitaxel, an antirestenotic drug proven in DEB applications. The coating technology has been proven in several clinical studies performed by Eurocor, including the global Valentine I and II registries. The proprietary coating employed in these DEB products is capable of delivering the antirestenotic drug consistently during very brief inflation times, while also minimizing washout of the drug during delivery and placement of the DEB.
Following CE Mark approval currently anticipated within the next six weeks, BioStream, BioPath 014 and BioPath 035 will be launched in major European markets and selected regions in the Middle East, Africa and Asia.
Company comments
for Biosensors
“We are delighted to have acquired a new range of leading DEBs as a result of this licensing agreement with Eurocor”, commented Jeffrey B. Jump, President of Biosensors’ Cardiovascular Division. “These innovative devices will complement our existing portfolio of cardiac stents, and facilitate our entry into the peripheral vascular disease market.”
“This arrangement with Eurocor is a positive development in the broadening of our cardiovascular business”, concluded Dr Jack Wang, CEO of Biosensors. “It also marks the first step in our expansion into the peripheral business.”
for Eurocor
“This agreement is further validation for Eurocor’s DEB products. There is considerable scope for global expansion within this rapidly-growing sector of the interventional devices market,” added Dr. Antonino Laudani, COO of Eurocor GmbH. “We are looking forward to working closely with Biosensors to further the process of establishing Eurocor as one of the leading global providers of innovative DEB products”.
